Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28460828 | 1.00 | HTT (0.59) | HTTALDH1A1MAPK1L3MBTL1MAPT | |
| SCHEMBL8488876 | 1.00 | HTT (0.59) | HTTALDH1A1MAPK1L3MBTL1MAPT | |
| SCHEMBL905777 | 1.00 | HTT (0.59) | HTTALDH1A1MAPK1L3MBTL1MAPT | |
| SCHEMBL16197784 | 1.00 | HTT (0.59) | HTTALDH1A1MAPK1L3MBTL1MAPT | |
| SCHEMBL17004058 | 1.00 | HTT (0.59) | HTTALDH1A1MAPK1L3MBTL1MAPT | |
| SCHEMBL8854045 | 1.00 | HTT (0.59) | HTTALDH1A1MAPK1L3MBTL1MAPT | |
| SCHEMBL9814068 | 1.00 | HTT (0.59) | HTTALDH1A1MAPK1L3MBTL1MAPT | |
| SCHEMBL8491249 | 1.00 | HTT (0.59) | HTTALDH1A1MAPK1L3MBTL1MAPT | |
| SCHEMBL3335775 | 1.00 | HTT (0.59) | HTTALDH1A1MAPK1L3MBTL1MAPT | |
| Sebacic Acid SCHEMBL28606878 | 1.00 | HTT (0.59) | HTTALDH1A1MAPK1L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115650852-B | Preparation method of octadecanedioic acid mono-tert-butyl ester | 天津卡普希科技有限公司 | 2023-03-17 | — | — | CN | claimed |
| CN-115650852-A | Preparation method of octadecanedioic acid mono-tert-butyl ester | 天津卡普希科技有限公司 | 2023-01-31 | — | — | CN | claimed |
| US-12178842-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2024-12-31 | — | — | US | disclosed |
| US-11820805-B2 | Conjugate based systems for controlled insulin delivery | MERCK SHARP & DOHME LLC (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| WO-2023175536-A1 | LIPID MONOMERS FOR THERAPEUTIC DELIVERY OF RNA | JANSSEN BIOTECH, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| EP-4204441-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-06-01 | — | — | US | disclosed |
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-06-01 | — | — | US | disclosed |
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-06-01 | — | — | US | disclosed |
| CN-110656134-B | Preparation method of monoester | 广东东阳光药业有限公司 | 2023-03-28 | — | — | CN | disclosed |
| WO-2007074133-A2 | COMPOSITIONS COMPRISING AN ACYLATED INSULIN AND ZINC AND METHOD OF MAKING THE SAID COMPOSITIONS | NOVO NORDISK A/S (DK) | 2007-07-05 | — | — | WO | disclosed |
| US-6897326-B2 | Asymmetrical bicipital lipid and tubular aggregate formed by using the same | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2005-05-24 | — | — | US | disclosed |
| US-20040120998-A1 | Novel asymmetrical bicipital lipid and tubular aggregate formed by using the same | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1396496-A1 | NOVEL ASYMMETRICALLY BICIPITAL LIPID AND TUBULAR AGGREGATE FORMED BY USING THE SAME | Japan Science and Technology Agency (JP) | 2004-03-10 | — | — | EP | disclosed |
| US-RE36359-E | SUCH AS N-(15-CARBOXYPENTADECANOYLOXY)SUCCINIMIDE; USED TO MODIFY PROTEINS TO OBTAIN PROTEIN DERIVATIVES HAVING IMPROVED BIOAVAILABILITY, NO ANTIGENICITY AND CAN BE ADMINISTERED TO ANIMALS | KURARAY CO., LTD. (JP) | 1999-10-26 | — | — | US | disclosed |
| EP-0511600-B1 | Long chain carboxylic acid imide ester | KURARAY CO (JP) | 1999-03-17 | — | — | EP | disclosed |
| US-5414089-A | Useful for modifying enzymes or proteins | KURARAY CO., LTD. (JP) | 1995-05-09 | — | — | US | disclosed |
| US-5336782-A | N-(carboxyalkoyloxy)succinimides; modifiers of proteins and enzymes to prolong their plasma half-lives; nontoxic; antitumor and -carcinogenic agents | KURARAY CO., LTD. (JP) | 1994-08-09 | — | — | US | disclosed |
| EP-0511600-A2 | Long chain carboxylic acid imide ester | KURARAY CO., LTD. (JP) | 1992-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820805-B2 | Conjugate based systems for controlled insulin delivery | GPR119, INSR, IGF1R | HTT 1774/4885ALDH1A1 1357/4885MAPK1 4342/4885 |
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | HTT 2214/4885ALDH1A1 4187/4885MAPK1 350/4885 |
| US-12178842-B2 | PCSK9 antagonist compounds | PCSK9, PCSK7, PCSK6 | HTT 2214/4885ALDH1A1 4187/4885MAPK1 350/4885 |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | HTT 2068/4885ALDH1A1 4716/4885MAPK1 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.